Targeting a diverse spectrum of cancers.

Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.

Platform

Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.

Pipeline

DCC-2618 KIT, PDGFRα
REBASTINIB TIE2
DCC-3014 CSF1R

Investors

DCPH

$38.21

0.00
07/16/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.

Latest News

Jun
20
2018
Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares Read More »
Jun
13
2018
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities 2018 Life Sciences Conference Read More »
Jun
11
2018
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock Read More »